Panbela announces publication of preclinical data titled: expanded potential of the polyamine analogue sbp-101 (diethyl dihydroxyhomospermine) as a modulator of polyamine metabolism and cancer therapeutic

Minneapolis, june 28, 2022 (globe newswire) --  panbela therapeutics, inc . - (nasdaq: pbla), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the publication of preclinical data from studies of sbp-101 that demonstrated a 42% increase in median survival in a mouse model of vdid8+ ovarian cancer. data published in the international journal of molecular sciences also showed sbp-101 delayed tumor progression and decreased the overall tumor burden. sbp-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (pmi) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. the company expects to initiate an ovarian cancer clinical program for sbp-101 during 2022.
PBLA Ratings Summary
PBLA Quant Ranking